Abstract:Abstract The most common cause of inherited melanoma is mutations in the CDKN2A gene, which is a gene regulator of cell division. The risk of melanoma in carriers of this gene is 30% by 50 years and 67% by 80 years (Goldstein AM, Fraser MC, Struewing JP et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333: 970–5). Fortunately, germline mutation in the CDKN2A gene is believed to be rare in the population (Harland M, Cust AE, Badenas C et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract 2014; 12: 20). Those positive with the CDKN2A gene have associated risks of developing other malignancies such as lung, breast, brain and, in particular, pancreatic carcinoma. Pancreatic cancer is associated with smoking and alcohol-induced pancreatitis. To the best of our knowledge no study has mapped out an extensive CDKN2A mutation-positive family tree including second-degree relatives. We have mapped a family tree including first- and second-degree relatives, stemming from our index patient. She was the first in her family to be diagnosed with malignant melanoma, at the age of 33 years. She tested positive for the CDKN2A gene mutation, BRAF wildtype. Our patient had 10 first-degree relatives. To date, four of these relatives have been diagnosed with malignant melanoma. Her son was diagnosed with malignant melanoma at the age of 12 years and was also found to be positive for the CDKN2A mutation. Four of her other first-degree relatives have been diagnosed with other malignancies: lung adenocarcinoma, squamous cell carcinoma, breast cancer and chordoma. No diagnosis of pancreatic carcinoma has been made in a first-degree relative. There are 21 second-degree relatives, with only one confirmed malignant melanoma. Not all family members have been tested for the CDKN2A mutation, and confounding factors include lifestyle and sun exposure. However, this family tree clearly shows the spread of the condition through a family, with the mutation present in a non-Mendelian pattern. More cohorts need to be collected to accurately predict the risk of malignancy and correction of preventable factors. Being genetically tested for the CDKN2A mutation is beneficial for patients and their families as appropriate counselling can be provided. Patients would be better informed in continued skin self-examination, sun protection and risk of other malignancies.

Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades

Pediatric Melanoma in Melanoma-Prone Families.

Phenocopies in Melanoma-Prone Families with Germ-Line CDKN2A Mutations

P069 Familial malignant melanoma: CDKN2A mutation-positive family tree

The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of <i>CDKN2A</i> and <i>CDK4</i>

Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.

Melanoma Prone Families with CDK4 Germline Mutation: Phenotypic Profile and Associations with MC1R Variants.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

Rare Germline Copy Number Variations and Disease Susceptibility in Familial Melanoma.

Cell Senescence and the Genetics of Melanoma Development

Germline Cancer Susceptibility in Individuals with Melanoma

Constitutive Mitochondrial DNA Copy Number in Peripheral Blood of Melanoma Families with and Without CDKN2A Mutations.

Rare Germline Variants in Known Melanoma Susceptibility Genes in Familial Melanoma

Telomere Length and the Risk of Cutaneous Malignant Melanoma in Melanoma-Prone Families with and Without CDKN 2 A Mutations

Prevalence of CDKN2A, CDK4, POT1, BAP1, MITF, ATM, and TERT Pathogenic Variants in a Single-Center Retrospective Series of Patients With Melanoma and Personal or Family History Suggestive of Genetic Predisposition

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families

Genetic testing for familial melanoma

Family History of Melanoma and Parkinson Disease Risk

Estimating CDKN2A Mutation Carrier Probability among Global Familial Melanoma Cases Using GenoMELPREDICT.

Abstract A84: Reduced LINE-1 methylation in peripheral blood mononuclear cells is associated with risk of melanoma in families segregating CDKN2A germline mutations

Histologic Features of Melanoma Associated with Germline Mutations of CDKN2A, CDK4, and POT1 in Melanoma-Prone Families from the United States, Italy, and Spain.